SELLAS Outlines 2025 Objectives: Phase 3 REGAL Interim Analysis In January, Phase 2 SLS009 Topline Data And FDA Review Expected 1H 2025, Tambiciclib Named As INN For SLS009, Non-Dilutive Grant Funding Application Submitted For AML Expansion, And...

BenzingaJan 8 21:24

Express News | Sellas Life Sciences Group Inc: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 for Sls009

BreakingsJan 8 21:20

SELLAS Announces Key Business Objectives for 2025

GlobeNewswireJan 8 21:20

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 Am ET

GlobeNewswireJan 2 21:00

Promising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences' SLS009

TipRanksDec 11, 2024 21:05 · Ratings

Express News | Sellas Life Sciences Group: Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating Interim Analysis

BreakingsDec 10, 2024 21:33